Biblioteca

Convalescent Plasma to Treat COVID-19

Recent discovery and development of inhibitors targeting coronaviruses

Drug treatment options for the 2019-new coronavirus (2019- nCoV)

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options

The convalescent sera option for containing COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Of chloroquine and COVID-19

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Harnessing the immune system via FcγR function in immune therapy A pathway to next- gen mAbs

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Reducing mortality from 2019-nCoV host-directed therapies should be an option

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19

Clinical trials on drug repositioning for COVID-19 treatment

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Preparing for a COVID19 pandemic

Medidas preventivas

Taking the right measures to control COVID-19

Medidas preventivas

«
1
2
3
4
5
6
7
8
9
10
...
21
22
»

Institucional

Membros

Meios

Contáctenos